Skip to main content

Table 3 Summary of adverse events during triple antiplatelet therapy(significant effects are in bold).

From: Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis

Patients

Intervention

Major bleeding

Minor bleeding

Blood transfusions

Thrombocytopenia

  

Triple

events/total

Control

events/total

OR *(95% CI)

Triple

events/total

Control

events/total

OR* (95% CI)

Triple

events/total

Control

events

/total

OR* (95% CI)

Triple

events/total

Control

events/total

OR* (95% CI)

NSTE-ACS

GP IIb/IIIa

34/1275

30/1274

1.15 (0.69-1.91)

46/1113

34/1111

1.37 (0.81-2.33)

45/1174

36/1173

1.27 (0.81-2.00)

8/1012

0/1010

17.1 (0.99-296.69)

STEMI

GP IIb/IIIa

11/255

2/195

1.86 (0.43-8.17)

23/255

7/195

2.73 (1.15-6.46)

10/281

15/272

0.63 (0.28-1.44)

11/238

4/181

1.51 (0.48-4.71)

 

Cilostazol

0/30

0/30

          

Elective PCI

GP IIb/IIIa

42/3314

34/3309

1.29 (0.70-2.36)

99/3314

62/3309

1.60 (1.16-2.21)

71/3264

40/3263

1.79 (1.14-2.79)

17/2269

0/2250

8.04 (1.82-35.59)

 

Cilostazol

0/1054

1/1058

0.33 (0.01-8.24)

6/1054

7/1058

0.85(0.28-2.56)

   

1/450

2/450

0.62 (0.08-5.09)

 

Clopidogrel

1/60

0/60

3.10 (0.12-79.29)

1/60

0/60

3.10 (0.12-79.23)

      
  1. *Odds ratios were calculated from random effect models.
  2. NSTE-ACS, non-ST elevation acute coronary syndromes; STEMI, ST elevation myocardial infarction; PCI, percutaneous coronary intervention.